Market Cap | 13.12M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -7.42M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -6.00% |
Sales | 60k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -16.00% |
Dividend | N/A | Price/Book | 0.70 | EPS next 5Y | - | 52W High Chg | -53.00% |
Recommedations | - | Quick Ratio | 37.95 | Shares Outstanding | 329.65M | 52W Low Chg | 101.00% |
Insider Own | 1.31% | ROA | -17.15% | Shares Float | 326.15M | Beta | 1.10 |
Inst Own | - | ROE | -53.26% | Shares Shorted/Prior | -/- | Price | 0.03 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 9,990 | Target Price | - |
Oper. Margin | -1,631.67% | Earnings Date | Feb 29 | Volume | 1,600 | Change | 0.00% |
Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. It engages in the implementation and licensing of its technologies and formulations to deliver molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and others. The company offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, it provides licensed Agrarius, an agricultural plant signalling technology. The company is headquartered in Concord, Canada.